Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
Kubilay KaraboyunEyyüp CavdarYakup İriağaçAbdussamet CelebıTanju KapaganIlkay GulturkOzden DemırOkan AvcıErdoğan Selçuk ŞeberPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)
We found that tamoxifen had increased the risk of urinary incontinence compared to aromatase inhibitors in patients receiving hormone therapy for breast cancer. In addition, we showed that age and hypertension were also independent predictors for UI. In the context of quality of life, we recommend close follow-up of these patients, as drug adherence may be affected in the event of urinary incontinence.
Keyphrases
- urinary incontinence
- end stage renal disease
- blood pressure
- newly diagnosed
- ejection fraction
- chronic kidney disease
- breast cancer cells
- prognostic factors
- early stage
- stem cells
- peritoneal dialysis
- adipose tissue
- postmenopausal women
- insulin resistance
- young adults
- mesenchymal stem cells
- skeletal muscle
- drug induced
- glycemic control